Skip to main content
. 2019 Jun 2;1(7):303–311. doi: 10.1253/circrep.CR-19-0047

Table 1.

Patient Baseline Characteristics

  Group H
(n=87)
Group G
(n=42)
P-value
Age (years) 51.9±17.0 57.2±15.7 0.090
Male 29 (33) 16 (38) 0.800
BSA (L/min/m2) 1.51±0.22 1.57±0.19 0.144
WHO II/III/IV 27/41/19 11/19/12 0.504
IPAH/CD/PPH/CHD 38/31/4/14 17/12/7/6 0.142
Laboratory data
 BNP (pg/mL) 238 (46–403) 410 (69–573) 0.084
 UA (mg/dL) 6.6±2.2 7.2±2.9 0.196
 Cr (mg/dL) 0.91±0.67 0.85±0.28 0.506
Echocardiography
 TRPG (mmHg) 59.4±25.3 64.5±25.4 0.315
 TAPSE (mm) 14.2±6.2 16.5±5.4 0.307
Cardiac catheterization
 PAWP (mmHg) 11.3±4.3 10±4.7 0.141
 Systolic PAP (mmHg) 73.6±30.1 70.3±19.6 0.455
 Diastolic PAP (mmHg) 31.0±15.7 27.6±9.5 0.140
 Mean PAP (mmHg) 48.2±19.6 44.2±11.9 0.153
 PVR (Wood unit) 7.1±6.4 9.5±6.4 0.121
 RAP (mmHg) 6.3±4.8 6.6±5.1 0.344
 SvO2 (%) 65.5±12.3 64.2±9.8 0.633
 CO (L/min) 4.79±1.75 4.38±1.5 0.205
 CI (L/min/m2) 3.12±1.21 2.74±0.86 0.082
 Heart rate (beats/min) 84±14 83±15 0.863

Data given as mean±SD, n (%) or median (range). BNP, brain natriuretic peptide; BSA, body surface area; CD, collagen disease; CHD, congenital heart disease; CI, cardiac index; CO, cardiac output; Cr, creatinine; Group G, goal-oriented sequential combination therapy; Group H, conventional empiric therapy; IPAH, idiopathic pulmonary arterial hypertension; PAH, pulmonary arterial hypertension; PAP, pulmonary arterial pressure; PAWP, pulmonary artery wedge pressure; PPH, portopulmonary hypertension; PVR, pulmonary vascular resistance; RAP, right atrial pressure; SvO2, mixed venous oxygen saturation; TAPSE, tricuspid annular plane systolic excursion: TRPG, trans regurgitation pressure gradient; UA, uric acid; WHO, World Health Organization.

HHS Vulnerability Disclosure